Drug interaction study launches: will BV100 change how polymyxin b works?
NCT ID NCT07580586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether a new drug called BV100 changes how the body processes the antibiotic polymyxin B. Sixteen healthy adults will receive polymyxin B alone and then again with BV100 to compare drug levels. The goal is not to treat disease but to gather safety and dosing information for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BV100 and polymyxin B
- What this could lead to
- If successful, this could help doctors adjust polymyxin B doses when given with BV100, potentially improving safety and effectiveness in future patients.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only measures drug levels, not treatment outcomes, so results may not apply to sick individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of Vienna
RECRUITINGVienna, 1090, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ACC017 be safely dosed? a trial seeks answers
- Can a fingerprint scan replace traditional drug tests?
- Gut feeling: could probiotics soothe the mind?
- A window to the brain? eye signals may track dopamine
- Can a common heartburn pill change how a cancer drug works?
- Breathing exercises may rewire tongue control — a pilot study puts the idea to the test